帕罗西汀联合不同剂量奥氮平治疗抑郁症伴睡眠障碍患者的临床疗效观察  

Clinical observation of paroxetine combined with different doses of olanzapine in the treatment of patients with depression and sleep disorders

作　　者：李志鹏[1] 佘继祥[1] 李家磊[1] 郑琼 LI Zhi-peng;SHE Ji-xiang;LI Jia-lei(Clinical Psychology Department,Yunnan Psychiatric Hospital,Kunming 650224,China)

机构地区：[1]云南省精神病医院临床心理科二区,650224

出　　处：《中国现代药物应用》2022年第18期27-30,共4页Chinese Journal of Modern Drug Application

摘　　要：目的探讨帕罗西汀联合不同剂量奥氮平治疗抑郁症伴睡眠障碍患者的临床疗效。方法90例抑郁症伴睡眠障碍患者为研究对象,依据乱数表法随机分为对照组、高剂量组和低剂量组,各30例。对照组采用帕罗西汀治疗,高剂量组采用高剂量奥氮平(10 mg)联合帕罗西汀治疗,低剂量组采用低剂量奥氮平(5 mg)联合帕罗西汀治疗。对比三组临床疗效、焦虑情况、抑郁情况、睡眠质量、生活质量及不良反应发生情况。结果低剂量组治疗总有效率93.33%高于高剂量组的73.33%及对照组的46.67%,高剂量组治疗总有效率高于对照组,差异均有统计学意义(P<0.05)。治疗后,对照组汉密尔顿焦虑量表(HAMA)评分为(17.15±4.51)分、汉密尔顿抑郁量表(HAMD)评分为(20.06±5.28)分、匹茨堡睡眠质量指数(PSQI)评分为(13.68±4.27)分;高剂量组HAMA评分为(12.01±3.20)分、HAMD评分为(16.45±4.39)分、PSQI评分为(11.33±3.65)分;低剂量组HAMA评分为(8.83±1.95)分、HAMD评分为(13.12±3.94)分、PSQI评分为(8.29±3.34)分。治疗后,三组HAMA评分、HAMD评分及PSQI评分均低于本组治疗前,且低剂量组低于高剂量组与对照组,高剂量组低于对照组,差异均有统计学意义(P<0.05)。治疗后,三组物质生活状态评分、躯体功能评分、社会功能评分、心理功能评分均高于本组治疗前,且低剂量组高于高剂量组与对照组,高剂量组高于对照组,差异均有统计学意义(P<0.05)。三组不良反应发生率对比,差异无统计学意义(P>0.05)。结论抑郁症伴睡眠障碍患者采用帕罗西汀联合低剂量奥氮平治疗具有较高的临床疗效,可改善焦虑抑郁症状,提高睡眠及生活质量,安全性较高,可为临床治疗提供参考。Objective To discuss the clinical efficacy of paroxetine combined with different doses of olanzapine in the treatment of patients with depression and sleep disorders.Methods A total of 90 patients with depression and sleep disorders were selected as the research subjects.According to the random numerical table,they were randomly divided into the control group,the high-dose group and the low-dose group,with 30 cases in each group.The control group was treated with paroxetine,the high-dose group was treated with high-dose olanzapine(10 mg)combined with paroxetine,and the low-dose group was treated with low-dose olanzapine(5 mg)combined with paroxetine.The clinical efficacy,anxiety,depression,sleep quality,quality of life and occurrence of adverse reactions were compared among the three groups.Results The total effective rate of treatment 93.33%in the low-dose group was higher than 73.33%in the high-dose group and 46.67%in the control group,and the differences were statistically significant(P<0.05).After treatment,the Hamilton Anxiety Scale(HAMA)score in the control group was(17.15±4.51)points,the Hamilton Depression Scale(HAMD)score was(20.06±5.28)points,and the Pittsburgh Sleep Quality Index(PSQI)score was(13.68±4.27)points;in the high-dose group,the HAMA score was(12.01±3.20)points,the HAMD score was(16.45±4.39)points,and the PSQI score was(11.33±3.65)points;in the low-dose group,the HAMA score was(8.83±1.95)points,the HAMD score was(13.12±3.94)points,and the PSQI score was(8.29±3.34)points.After treatment,the HAMA score,HAMD score and PSQI score in the three groups were lower than those before treatment in this group;the low-dose group was lower than the high-dose group and the control group,and the high-dose group was lower than the control group;the differences were all statistically significant(P<0.05).After treatment,the scores of material life status,physical function,social function,and psychological function of the three groups were higher than those of this group before treatment;the low-dose gr

关 键 词：抑郁症 奥氮平 帕罗西汀 睡眠障碍 生活质量 

分 类 号：R749.4[医药卫生—神经病学与精神病学] R740[医药卫生—临床医学]